Fractyl Health, Inc. (GUTS) Cash Flow Statement
Where GUTS’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- −$90.3M
- Capital expenditures
- $557,000
- Free cash flow
- −$90.9M
- Returned to shareholders
- —
- Change in cash
- $14.1M cash at year-end $85.8M
Cash from operations
−$90.3M
Capital expenditures
−$557,000
Net borrowing (repayment)
−$457,000
Shares issued
+$85.4M
Other financing
+$20.0M
Change in cash
$14.1M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GUTS operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
GUTS cash flow trends, FY2019–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$27.7MFY2019 | −$90.3MFY2025 | — | |
| Capital expenditures | $97,000FY2019 | $557,000FY2025 | +33.8%/yr | |
| Free cash flow | −$27.8MFY2019 | −$90.9MFY2025 | — | |
| Free cash flow margin | −35,985.0%FY2023 | −72,350.5%FY2024 | −36,365.5 pts | |
| Stock-based compensation | $2.5MFY2019 | $6.7MFY2025 | +17.7%/yr | |
| Capex / revenue | 299.2%FY2023 | 1,897.8%FY2024 | +1,598.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GUTS cash flow by activity
OperatingInvestingFinancingChange in cash
GUTS net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GUTS cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$141.0M | −$68.7M | −$77.1M | −$46.5M | −$38.7M | −$30.5M | −$30.6M |
| Depreciation & amortization | $1.1M | $677,000 | $286,000 | $452,000 | $676,000 | $770,000 | $893,000 |
| Stock-based compensation | $6.7M | $14.4M | $4.3M | $3.1M | $2.1M | $1.6M | $2.5M |
| Change in working capital | −$395,000 | $9.6M | $989,000 | −$1.2M | $1.7M | −$3.5M | −$824,000 |
| Other non-cash items | $43.2M | −$21.5M | $28.7M | −$2.1M | $795,000 | $517,000 | $274,000 |
| Cash from operating activities | −$90.3M | −$65.5M | −$42.8M | −$46.2M | −$33.5M | −$31.1M | −$27.7M |
| Investing activities | |||||||
| Capital expenditures | −$557,000 | −$1.8M | −$359,000 | −$56,000 | −$51,000 | −$2,000 | −$97,000 |
| Investments (net) | — | −$1.8M | −$359,000 | −$56,000 | −$51,000 | −$2,000 | — |
| Acquisitions & other investing | $0 | $1.8M | — | $56,000 | $51,000 | $2,000 | $0 |
| Cash from investing activities | −$557,000 | −$1.8M | — | −$56,000 | −$51,000 | −$2,000 | −$97,000 |
| Financing activities | |||||||
| Net borrowing (repayment) | −$457,000 | −$187,000 | $28.3M | $4.0M | −$7,000 | — | — |
| Shares issued | $85.4M | $103.7M | $0 | $0 | $99.8M | $54.4M | $0 |
| Other financing | $20.0M | −$2.3M | −$911,000 | $321,000 | $40,000 | $17,000 | $15.2M |
| Cash from financing activities | $105.0M | $101.2M | $27.4M | $4.3M | $99.9M | $54.4M | $15.2M |
| Summary | |||||||
| Net change in cash | $14.1M | $33.9M | −$15.7M | −$46.2M | $66.4M | $23.3M | −$12.7M |
| Cash at end of period | $85.8M | $71.7M | $33.5M | $49.3M | $95.5M | $29.1M | $5.8M |
| Free cash flow | −$90.9M | −$67.3M | −$43.2M | −$46.3M | −$33.5M | −$31.1M | −$27.8M |
| Free cash flow margin | — | −72,350.5% | −35,985.0% | — | — | — | — |
| Capex / revenue | — | 1,897.8% | 299.2% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$25.5M | $9.2M | −$43.7M | −$45.6M | −$27.9M | −$23.7M | −$25.0M | −$23.2M | −$17.2M | −$3.3M | −$19.2M | −$15.7M |
| Depreciation & amortization | $278,000 | $281,000 | $279,000 | $290,000 | $270,000 | $290,000 | $223,000 | $209,000 | $192,000 | $53,000 | $38,000 | $84,000 |
| Stock-based compensation | $2.5M | $2.5M | $1.9M | $1.6M | $1.8M | $1.4M | $2.9M | $2.5M | $3.8M | $5.2M | $1.3M | $1.1M |
| Change in working capital | $1.1M | −$4.5M | −$218,000 | −$1.5M | $3.2M | −$1.9M | $5.0M | $2.1M | −$958,000 | $3.4M | $1.2M | −$321,000 |
| Other non-cash items | $5.7M | −$30.0M | $20.5M | $22.5M | $1.4M | −$1.1M | −$167,000 | $258,000 | −$4.5M | −$17.1M | $6.1M | $3.9M |
| Cash from operating activities | −$15.9M | −$22.5M | −$21.3M | −$22.7M | −$21.2M | −$25.1M | −$17.0M | −$18.0M | −$18.7M | −$11.7M | −$10.6M | −$11.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | −$3,000 | −$8,000 | −$98,000 | −$448,000 | −$233,000 | −$213,000 | −$260,000 | −$1.1M | −$136,000 | −$148,000 |
| Investments (net) | — | — | — | −$8,000 | −$98,000 | −$448,000 | −$233,000 | −$213,000 | −$260,000 | −$1.1M | −$136,000 | −$148,000 |
| Acquisitions & other investing | — | — | $0 | $8,000 | $98,000 | $448,000 | $233,000 | $213,000 | $260,000 | $1.1M | — | $148,000 |
| Cash from investing activities | — | — | −$3,000 | −$8,000 | −$98,000 | −$448,000 | −$233,000 | −$213,000 | −$260,000 | −$1.1M | — | −$148,000 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | $170,000 | $170,000 | — | — | — | — | — | — | — | — | — | — |
| Net borrowing (repayment) | −$127,000 | −$123,000 | −$119,000 | −$117,000 | −$112,000 | −$109,000 | −$106,000 | −$58,000 | — | — | — | — |
| Shares issued | $0 | $170,000 | $5.6M | $78.2M | $1.6M | $0 | $0 | $0 | $0 | $103.7M | $0 | $0 |
| Other financing | −$170,000 | $3.9M | $19.7M | $0 | $0 | $280,000 | $173,000 | $220,000 | −$5,000 | −$2.7M | −$556,000 | $28.0M |
| Cash from financing activities | −$127,000 | $4.1M | $25.2M | $78.1M | $1.5M | $171,000 | $67,000 | $162,000 | −$5,000 | $101.0M | −$556,000 | $28.0M |
| Summary | ||||||||||||
| Net change in cash | −$16.0M | −$18.4M | $3.9M | $55.4M | −$19.8M | −$25.4M | −$17.2M | −$18.1M | −$19.0M | $88.2M | −$11.3M | $16.8M |
| Cash at end of period | $51.4M | $63.2M | $85.8M | $77.7M | $26.5M | $46.4M | $71.7M | $84.7M | $107.0M | $126.0M | $33.5M | $49.1M |
| Free cash flow | −$15.9M | −$22.5M | −$21.3M | −$22.7M | −$21.3M | −$25.5M | −$17.3M | −$18.3M | −$19.0M | −$12.8M | −$10.7M | −$11.2M |
| Free cash flow margin | — | — | — | — | — | — | −575,566.7% | −130,371.4% | −44,179.1% | −38,697.0% | −153,357.1% | −31,016.7% |
| Capex / revenue | — | — | — | — | — | — | 7,766.7% | 1,521.4% | 604.7% | 3,209.1% | 1,942.9% | 411.1% |
| Operating cash flow / net income | — | −2.44 | — | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
GUTS cash generation
In fiscal 2025 (ended September 30, 2025), Fractyl Health generated -$90.3 million of cash from operations and spent $0.6 million on capital expenditures, leaving free cash flow of -$90.9 million. Cash and equivalents rose by $14.1 million over the year.
Related: GUTS income statement, GUTS balance sheet. See the GUTS stock overview for the latest quote and news.
GUTS cash flow FAQ
What is Fractyl Health's free cash flow?
Fractyl Health's free cash flow was -$90.9 million in fiscal 2025: -$90.3 million of operating cash flow minus $0.6 million of capital expenditures It was -$67.3 million a year earlier..
How much cash does Fractyl Health generate from operations?
Fractyl Health generated -$90.3 million of cash from operating activities in fiscal 2025.
How much does Fractyl Health spend on capital expenditures?
Fractyl Health spent $0.6 million on capital expenditures in fiscal 2025, compared with $1.8 million the year before.